Acurx Change In Working Capital from 2010 to 2024
| ACXP Stock | USD 1.25 0.10 8.70% |
Change In Working Capital | First Reported 2010-12-31 | Previous Quarter 30 K | Current Value 28.5 K | Quarterly Volatility 593.8 K |
Check Acurx Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acurx Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 15.3 M, Interest Expense of 1.3 K or Selling General Administrative of 6.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 9.88. Acurx financial statements analysis is a perfect complement when working with Acurx Pharmaceuticals Valuation or Volatility modules.
Acurx | Change In Working Capital |
Latest Acurx Pharmaceuticals' Change In Working Capital Growth Pattern
Below is the plot of the Change In Working Capital of Acurx Pharmaceuticals LLC over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. Acurx Pharmaceuticals' Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acurx Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Change In Working Capital | 10 Years Trend |
|
Change In Working Capital |
| Timeline |
Acurx Change In Working Capital Regression Statistics
| Arithmetic Mean | 740,156 | |
| Coefficient Of Variation | 80.22 | |
| Mean Deviation | 474,929 | |
| Median | 1,045,556 | |
| Standard Deviation | 593,763 | |
| Sample Variance | 352.6B | |
| Range | 2M | |
| R-Value | (0.57) | |
| Mean Square Error | 254.4B | |
| R-Squared | 0.33 | |
| Significance | 0.03 | |
| Slope | (76,275) | |
| Total Sum of Squares | 4.9T |
Acurx Change In Working Capital History
About Acurx Pharmaceuticals Financial Statements
Acurx Pharmaceuticals shareholders use historical fundamental indicators, such as Change In Working Capital, to determine how well the company is positioned to perform in the future. Although Acurx Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Acurx Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Acurx Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Change In Working Capital | 30 K | 28.5 K |
Pair Trading with Acurx Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acurx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Acurx Stock
| 0.72 | VTRS | Viatris | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.69 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.58 | GILD | Gilead Sciences | PairCorr |
| 0.47 | WAT | Waters | PairCorr |
The ability to find closely correlated positions to Acurx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acurx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acurx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acurx Pharmaceuticals LLC to buy it.
The correlation of Acurx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acurx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acurx Pharmaceuticals LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acurx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.